Two Survival Cuts, One Silent Substitution: The Lurbinectedin Joint Clinical Assessment
Mondher Toumi, Samuel Aballéa, Laurent Boyer, Maarten Postma et autres
This methodological commentary examines the Joint Clinical Assessment (JCA) report of lurbinectedin combined with atezolizumab as maintenance therapy for extensive-stage small-cell lung cancer, based on the phase 3 IMforte trial. The JCA's evaluation rests on two overall survival data cuts: a confirmatory, …